Ocugen shares rise 10.49% intraday after OCU410 gene therapy shows 46% reduction in lesion growth in phase II trial with no serious adverse events.

Ocugen surged 10.49% in intraday trading, driven by the company's announcement of preliminary 12-month phase 2 trial data for its OCU410 gene therapy targeting geographic atrophy secondary to dry age-related macular degeneration. The results showed a 46% reduction in lesion growth compared to the control group, with no related serious adverse events. Ocugen plans to initiate phase 3 trials in 2026 and maintains its goal of submitting a biologics license application by 2028.